Primary cardiovascular disease prevention is leaving the office
2014-03-31
(Press-News.org) MINNEAPOLIS, MN – March 30, 2014 – Early results from HeartBeat Connections, a telemedicine program supported by the Minneapolis Heart Institute Foundation (MHIF), suggest effective primary prevention for cardiovascular disease (CVD) may be achieved with a team-based approach that integrates office visits with supplemental phone coaching. HeartBeat Connections provides dietitian- and nurse-led coaching over the phone to adults at high risk for CVD, with the goal of helping to improve and control key CVD risk factors. Gretchen Benson, RD, CDE, Healthcare Systems Integration Manager at the MHIF, will present six-month data from the program at the American College of Cardiology (ACC) conference in Washington, DC today.
As part of the broader Hearts Beat Back: The Heart of New Ulm Project, 1,035 adults aged 40-79 with metabolic syndrome or high Framingham Risk Scores were identified via electronic health record data and invited to participate in the HeartBeat Connections program. Over six months, the participants (333) showed significant improvement in fruit and vegetable consumption, physical activity, stress reduction, aspirin use, and medication adherence. Researchers also noted a significant improvement in LDL ("bad" cholesterol) levels and smoking status — the proportion of adults achieving an LDL level < 100 mg/dL increased by 70% in participants (333) and by only 24% in nonparticipants (702). "We're encouraged by the results we've seen so far," states lead researcher Gretchen Benson. "Real-world, systems-based innovations like HeartBeat Connections can serve as a model to target and engage at-risk populations, thereby enhancing primary CVD care in underserved areas."
When it comes to primary CVD prevention, persistence may be key. Adults who engaged in five or more HeartBeat Connections coaching sessions showed a greater degree of improvement in LDL levels, medication adherence, and stress reduction than those who had fewer than five coaching sessions and those who did not participate at all. Improvements in the nonparticipant group, although less significant, may be attributed in part to the broader Heart of New Ulm Project (of which HeartBeat Connections is just one part), which provides health interventions throughout the community.
INFORMATION:
About the Hearts Beat Back: The Heart of New Ulm Project
Hearts Beat Back is a 10-year demonstration project aimed at reducing heart attacks and CVD in a rural Minnesota community (New Ulm, Minnesota). The project is a collaboration between the Minneapolis Heart Institute Foundation, Allina Health and the community of New Ulm.
About the Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation is dedicated to improving people's lives through the highest quality cardiovascular research and education.
Scientific Innovation and Research — Publishing more than 120 peer-reviewed studies each year, MHIF is a recognized research leader in the broadest range of cardiovascular medicine. Each year, cardiologists and hospitals around the world adopt MHIF protocols to save lives and improve patient care.
Education and Outreach — Research shows that modifying specific health behaviors can significantly reduce the risk of developing heart disease. Through community programs, screenings and presentations, MHIF educates people of all walks of life about heart health. The goal of the Foundation's community outreach is to increase personal awareness of risk factors and provide the tools necessary to help people pursue heart- healthy lifestyles.
About the Minneapolis Heart Institute®
The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.
ELSE PRESS RELEASES FROM THIS DATE:
Adults with inherited high cholesterol are underdiagnosed and undertreated
2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – An estimated 1 in 500 people worldwide suffer from familial hypercholesterolaemia (FH), an inherited condition of extremely high cholesterol that is associated with premature heart disease and death. Despite this high prevalence, recent research funded by the Minneapolis Heart Institute Foundation (MHIF) confirms FH is underdiagnosed and undertreated. Thomas Knickelbine, MD, Preventive Cardiology Director at the Minneapolis Heart Institute at Abbott Northwestern Hospital, will present the results of research aimed at identifying just ...
Evolocumab superior to ezetimibe in lowering LDL cholesterol
2014-03-31
WASHINGTON (March 30, 2014) — Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session.
High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently ezetimibe is one of the few options ...
Head-to-head study favors balloon-expandable transcatheter heart valves
2014-03-31
WASHINGTON (March 30, 2014) — A first-ever randomized head-to-head comparison of two devices commonly used to treat the age-related disease aortic stenosis finds balloon-expandable transcatheter valves result in more successful procedures and relieve symptoms more frequently than self-expanding valves, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
Aortic stenosis is a condition in which a crucial valve in the heart ceases to function properly. The only cure is to replace the valve, either through open heart surgery ...
Higher risks without cardio benefits halt study of aleglitazar
2014-03-31
WASHINGTON (March 30, 2014) — The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal bleeding with no offsetting cardiovascular benefits, according to data presented at the American College of Cardiology's 63rd Annual Scientific Session. All other studies with the drug have been stopped as well.
Aleglitazar sparked interest for this patient population because of its dual action on two subtypes of the PPAR ...
Darapladib falls short in chronic coronary heart disease
2014-03-31
WASHINGTON (March 30, 2014) — The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot.
Darapladib ...
Evolocumab safely drops LDL cholesterol well below statin-only baseline
2014-03-31
WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 study presented at the American College of Cardiology's 63rd Annual Scientific Session.
LDL cholesterol is considered a major risk factor for cardiovascular disease. "High-risk patients – such as those with clinical cardiovascular disease, high LDL cholesterol levels or diabetes – are ideally treated with high-intensity ...
Anti-gout medication colchicine helps patients with recurrent pericarditis
2014-03-31
WASHINGTON (March 30, 2014) — A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first multicenter, double-blind trial to look at the use of colchicine for multiple recurrences of pericarditis, 240 patients were randomly assigned to either the study drug or placebo to examine the primary endpoint of recurrent pericarditis. The rate of disease recurrence ...
Renal denervation patient registry finds low rate of adverse events
2014-03-31
WASHINGTON (March 30, 2014) — Patients with uncontrolled high blood pressure treated with renal denervation had low rates of adverse events and significant lowering of blood pressure at six months, according to a registry-based study presented at the American College of Cardiology's 63rd Annual Scientific Session.
The Global SYMPLICITY Registry is the first and largest dataset of patients with uncontrolled hypertension treated with renal denervation. The open-label, multicenter study was established to examine the safety and effectiveness of the procedure. Outcomes presented ...
Post-approval study of transcatheter pulmonary valve completes 1 year
2014-03-31
WASHINGTON (March 30, 2014) — The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in a small sample of patients with certain congenital heart defects, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
This multi-center study of 100 patients consecutively implanted with the Melody transcatheter pulmonary valve between July 2010 and July 2012 assessed the effectiveness of the device at six and 12 months based on the percentage ...
Cardiac resynchronization improves survival in heart failure patients
2014-03-31
WASHINGTON (March 30, 2014) — Patients in mild heart failure who receive a specialized pacemaker known as cardiac resynchronization therapy with a defibrillator (CRT-D) may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first study to look at CRT-D in mildly symptomatic patients, researchers found that patients with left bundle branch block implanted with a CRT-D had a 41 percent reduced risk of death compared ...